NCT06930859 2026-03-16
ELEGANCE
Novartis
Recruiting
Clinical Trials
60 trialsNCT06016738 2026-03-13
OPERA-01
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07174336 2026-03-06
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT05307705 2026-03-02
PIKASSO-01
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05768139 2026-03-02
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT06905301 2026-02-20
IMPULSE
Novartis
Recruiting
NCT02763566 2026-02-05
MONARCH plus
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02246621 2026-02-03
MONARCH 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05161195 2026-02-02
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
Phase 4 Active not recruiting
NCT05514054 2026-01-29
EMBER-4
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02057133 2026-01-26
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Phase 1 Active not recruiting
NCT02779751 2026-01-26
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05645536 2026-01-12
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
Phase 3 Enrolling by invitation
NCT04556773 2025-12-17
DB-08
AstraZeneca
Phase 1 Active not recruiting
NCT06495164 2025-11-25
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Pfizer
Active not recruiting
NCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT04711252 2025-10-14
SERENA-4
AstraZeneca
Phase 3 Active not recruiting
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT05549505 2025-08-29
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Arvinas Inc.
Phase 2 Completed
NCT05257395 2025-07-17
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT03099174 2025-06-24
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT05952557 2025-06-19
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT06957379 2025-05-04
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Active not recruiting
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT03481998 2023-11-21
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Completed
NCT05780567 2023-04-21
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT02894398 2023-03-13
INGE-B
iOMEDICO AG
Phase 2 Completed
NCT03220178 2022-01-06
PRECYCLE
Palleos Healthcare GmbH
Phase 4 Terminated
NCT02441946 2020-06-17
neoMONARCH
Eli Lilly and Company
Phase 2 Completed
NCT00295620 2019-10-02
SALSA
AstraZeneca
Phase 3 Completed
NCT01597193 2019-05-08
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Pfizer
Phase 1 Completed
NCT00728949 2018-06-06
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01155089 2018-01-23
Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions
West-Ward Pharmaceutical
Phase NA Completed
NCT01155102 2018-01-23
Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions
West-Ward Pharmaceutical
Phase NA Completed
NCT00248170 2016-04-19
FACE
Novartis
Phase 3 Completed
NCT00081510 2015-04-15
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01151215 2014-07-25
MINT
AstraZeneca
Phase 2 Terminated
NCT00077025 2014-07-16
Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
AstraZeneca
Phase 2 Completed
NCT00022672 2013-06-13
A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00544986 2013-01-30
A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
AstraZeneca
Phase 4 Completed
NCT00537771 2013-01-25
HEART
AstraZeneca
Phase 4 Completed
NCT00605267 2012-09-06
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
AstraZeneca
Phase 3 Completed
NCT00259090 2012-08-16
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
AstraZeneca
Phase 2 Completed
NCT00256698 2012-08-01
FACT
AstraZeneca
Phase 3 Completed
NCT00323479 2012-04-06
Arthralgia During Anastrozole Therapy for Breast Cancer
AstraZeneca
Phase 4 Completed
NCT00143390 2012-01-25
Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer
Pfizer
Phase 3 Completed
NCT00555867 2011-12-23
PACT
AstraZeneca
Terminated
NCT00082277 2011-01-26
SABRE
AstraZeneca
Phase 4 Completed